Kev poob phaus: Ib txoj hauv kev tshiab rau Metabolic Regulation

Thaum lub Cuaj Hlis 29, 2025, Metsera (tau los ntawm Pfizer) tau tshaj tawm cov txiaj ntsig zoo los ntawm ob qhov kev poob phaus theem 1b (VESPER-1 thiab VESPER-13) ntawm MET-097i.

 

Semaglutide hmoov CAS 910463-68-2

1.Peb muab
(1) Tablet
(2) Cov
(3) Capsule
(4) Txau
(5) API (Ntshiab hmoov)
(6) Pill press machine
https://www.achievechem.com/pill-xwm
2.Customization:
Peb yuav sib tham tus kheej, OEM / ODM, Tsis muaj hom, rau kev tshawb nrhiav kev ruaj ntseg nkaus xwb.
PIB: BM-2-4-008
Semaglutide CAS 910463-68-2
Kev tshuaj xyuas: HPLC, LC-MS, HNMR
Kev them nyiaj yug Technology: R&D Dept.-4

Peb muabSemaglutide, thov xa mus rau lub vev xaib hauv qab no kom paub meej specifications thiab cov ntaub ntawv khoom.

Khoom siv:https://www.bloomtechz.com/synthetic-chemical/peptide/semaglutide-powder-cas-910463-68-2.html

MET-097i yog tus pioneering siab ncaj ncees, ua haujlwm ntev ntev GLP-1 receptor agonist (GLP-1 RA) nrog lub peev xwm rau kev txhaj tshuaj txhua hli.

Txoj kev tshawb fawb VESPER-1 (n=239) tau ntsuas qhov ua tau zoo thiab kev nyab xeeb ntawm MET-0971 (0.4mg-1.2mg, ib zaug ib lim tiam) rau 28 lub lis piam yam tsis muaj titration. Tam sim no peb tab tom tshawb fawb nthuav dav thiab ntsuas qhov ua tau zoo ntawm kev txhaj tshuaj qis dua. Txoj kev tshawb no VESPER-3 yog ib qho kev soj ntsuam tsis tu ncua uas muaj 268 tus neeg rog rog lossis rog rog, tsom rau kev ntsuas qhov ua tau zoo thiab kev ua haujlwm ntev ntawm MET-097 ntau zaus hauv ib hlis, thiab ntsuas qhov ua tau ntev ntawm ntau lub tswv yim nce koob tshuaj thaum lub sijhawm 12 lub lis piam soj ntsuam nruab nrab. Txoj kev tshawb no tau siv sijhawm 28 lub lis piam.

Hauv kev tshawb fawb VESPER-1, qhov nruab nrab qhov hnyav poob ntawm 0.4mg, 0.6mg, 0.9mg, thiab 1.2mg koob tshuaj pab pawg tom qab hloov cov placebo yog -8.1%, -10.0%, -13.0%, thiab -14.1%, feem. Tsis tas li ntawd, qhov siab tshaj plaws poob ntawm cov tib neeg hauv 1.2mg koob tshuaj tau mus txog -26.5%. Kev tshawb fawb VESPER-3 tam sim no tab tom ua thiab tsis muaj cov ntaub ntawv poob phaus muaj rau kev sib koom.

MET-097 tau pom cov chav kawm muaj peev xwm ua rau muaj kev zam rau hauv ob qho kev kawm. Hauv VESPER-1 txoj kev tshawb fawb, cov yam ntxwv ua siab ntev ntawm siab - koob tshuaj thiab tsis muaj titrated MET-097i zoo ib yam li cov tshuaj lag luam uas xav tau ntau qhov kev sib tw, nrog rau qhov kev pheej hmoo ntawm qhov sib txawv ntawm koob tshuaj ntawm 4% -23% rau xeev siab, 4% -15% rau ntuav 1.3% thiab raws plab Cov pawg koob tshuaj 1.2mg, uas tau ua tiav ob-kauj ruam titration, muaj qhov pheej hmoo tsawg tshaj plaws ntawm kev mob raws plab hauv txoj kev tshawb fawb VESPER-3.

Thaum lub Cuaj Hlis 30, 2025, Chengdu, Tuam Tshoj / Belgium Jimbros Radiolink Technology Co., Ltd. (tom qab no hu ua "Radiolink Technology"), lub tuam txhab kev kho mob tag nrho thoob ntiaj teb radiopharmaceutical therapy lub tuam txhab, tshaj tawm hnub no ua tiav ntawm $ 77 lab nyiaj txiag, suav nrog kwv yees li $ 50 lab nyiaj hauv Series C thiab cov nuj nqis. Qhov kev sib tw ntawm cov nyiaj txiag no yuav raug siv los txhawb kev tshawb fawb thiab kev loj hlob ntawm lub tuam txhab thoob ntiaj teb cov raj xa hluav taws xob thiab kev tsim kho cov chaw tsim khoom hauv Belgium. Nrog rau kev ua tiav ntawm cov nyiaj txiag no, Fulian Technology tau sau ze li ntawm $ 200 lab nyiaj txiag txij li thaum nws tsim xyoo 2021, suav nrog kev nqis peev nyiaj txiag, nuj nqis peev, thiab kev them nyiaj BD.

Qhov kev sib tw ntawm kev ncaj ncees nyiaj txiag no yog coj los ntawm Jiachen Capital, nrog ntau lub tuam txhab siab - zoo xws li Longpan Investment, Plaisance, thiab Zhenmai Investment ua cov tub ua lag luam. Cov tswv lag luam uas twb muaj lawm suav nrog Peev, Geding Venture Capital, Sequoia Tuam Tshoj Prosperity7, Xia Yan Capital thiab ntau lub koom haum txuas ntxiv mus nqis peev. Ntxiv nrog rau Series C kev ncaj ncees nyiaj txiag, lub tuam txhab kuj tau ua tiav kwv yees li $ 27 lab hauv cov nuj nqis qiv nyiaj raws li kev txhawb nqa nyiaj txiag yooj yim, uas yuav muab cov kev daws teeb meem ntxiv rau lub tuam txhab kev kho cov kav dej thiab kev tshawb nrhiav qhov project ntxov, thaum ua kom tiav kev ua tiav ntawm Belgian ntau lawm puag.

Hais txog Radiance Technology
Fulian Technology Co., Ltd. ("Fulian Technology") yog lub tuam txhab ua haujlwm thoob ntiaj teb kev kho mob radiopharmaceutical nyob rau theem kho mob, nrog chaw ua haujlwm hauv Belgium, Lub Tebchaws Yelemees, thiab Tuam Tshoj. Radiolink Technology tsom mus rau cov neeg mob thoob ntiaj teb thiab tau cog lus los tsim kom muaj kev lag luam thoob ntiaj teb cov tuam txhab tshuaj nuclear uas koom nrog kev tshawb fawb thiab kev tsim kho, kev tsim khoom, thiab kev lag luam ntawm cov tshuaj radiopharmaceuticals. Los ntawm kev ua cov kev tshawb fawb tshiab, nws daws cov teeb meem tseem ceeb uas tau ntsib los ntawm radiopharmaceuticals niaj hnub no thiab txhawb kev txhim kho kev kho mob yav tom ntej. Pab pawg Radiolink Technology yog tsim los ntawm pab pawg ua haujlwm tau zoo thiab cov kws paub txog kev paub txog kev paub txog kev ua neej nyob, kev tshawb fawb radioisotope, thiab kev kho mob.

Phase III qhov kev sim tshuaj ntsuam xyuas npaj rau npe 1000 yam kev kawm thiab xav tias yuav ua tiav los ntawm Lub Peb Hlis 2028.

Orforglipron tau ua tiav nyob rau theem III kev soj ntsuam kuaj mob ntshav qab zib thiab rog rog, thiab tab tom yuav xa daim ntawv thov rau npe raws li lub ntiaj teb thawj cov tshuaj me me GLP-1 receptor agonist.

Orforgipron yog ib qho me me molecule (tsis yog peptide) glucagon zoo li peptide-1 receptor agonist (GLP-1 RA) uas tam sim no nyob rau hauv txoj kev loj hlob thiab tswj qhov ncauj ib hnub ib zaug. Cov tshuaj no tuaj yeem noj txhua lub sijhawm ntawm hnub tsis muaj kev txwv rau kev noj zaub mov thiab dej. Cov tshuaj no tau tshawb pom los ntawm Chugai Pharmaceutical Co., Ltd. thiab tau tso cai rau kev txhim kho los ntawm Eli Lilly xyoo 2018.